Even though it is not yet a year since the first anti-Covid vaccines were presented , the main pharmaceutical companies around the world are already immersed in another race against time.

Now they are competing to be chosen to provide the booster doses that will certainly be needed in the US and the EU . The intensity with which companies like Pfizer or Moderna compete should not be surprising considering how much the stakes are.

Given the great resistance and ability to mutate of the Covid, everything indicates that this virus will become chronic, as has happened with the flu. In this way, booster doses will be necessary not only in 2022, but in subsequent years, which opens up a long-term business opportunity of great importance for the entire sector.

Even though it is not yet a year since the first anti-Covid vaccines were presented , the main pharmaceutical companies around the world are already immersed in another race against time.

Now they are competing to be chosen to provide the booster doses that will certainly be needed in the US and the EU . The intensity with which companies like Pfizer or Moderna compete should not be surprising considering how much the stakes are.

Given the great resistance and ability to mutate of the Covid, everything indicates that this virus will become chronic, as has happened with the flu. In this way, booster doses will be necessary not only in 2022, but in subsequent years, which opens up a long-term business opportunity of great importance for the entire sector.

By Sam Brad

The Great Writer and The Passionate Poet As Well, He Graduated from University Of Florida in Journalism and Brad have around 12 years of experience in news and media section.

Leave a Reply

Your email address will not be published. Required fields are marked *